Lytix To Take Lead Cancer Compound Into Clinic
The Scandinavian-based drug development company Lytix Biopharma announced its intention to take its lead anti-cancer molecule LTX-315 through to clinical trials. This decision follows the selection of Lytix's first lead antimicrobial compound towards end of 2007.The Immune System And Cancer - New Insights Into A Not Always Healthy Interplay
For a long time, scientists believed that the immune system acted to fight cancer development. However, recent findings demonstrate that the immune system also acts to promote cancer progression. At the International conference "Invasion and Metastasis" held at the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, Dr.Phase II Results For CDP791 In Non-small Cell Lung Cancer Support Further Clinical Development
UCB announces first results of its phase II exploratory study of CDP791, a specific VEGFR-2/KDR inhibitor, in combination with carboplatin and paclitaxel chemotherapy in first line non-small cell lung cancer (NSCLC). Positive improvements were observed on several efficacy endpoints including tumour response rate and time to tumour progression. The data support further late stage clinical development of the drug in first line NSCLC.03.28.08
Hairdressers and Barbers May Be At Increased Cancer Risk
A new report from the International Agency for Research on Cancer (IARC) finds that regular exposure to chemicals used in hair salons and barbershops may increase bladder cancer risk.Fighting Disfiguring Dermatologic Side Effects Of Cancer Treatment
Becky Sasaki has the quick laugh and easy smile of a woman who continues to thrive despite her four-year wrestling match with lung cancer. She still works every day in the family business, heads out for Thai food with her husband and baby sits for her energetic grandchildren.This winter when the cancer, which had metastasized, appeared in her brain for the third time, her oncologist prescribed a new breed of targeted cancer drugs to shrink the tumor.Taro Receives FDA Approval For Ondansetron Hydrochloride Injection USP, 2 Mg/mL ANDA
Taro Pharmaceutical Industries Ltd. ("Taro," the "Company," Pink Sheets: TAROF) reported that it has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Ondansetron Hydrochloride Injection USP, 2 mg/mL ("Ondansetron Injection"). Taro's Ondansetron Injection is used for the prevention of nausea and vomiting associated with chemotherapy.Basis Created For Directing And Filming Blood Vessels
A new method of filming blood-vessel cells that move in accordance with targeted signals has been developed by researchers at Uppsala University in collaboration with researchers at the University of California. The method can also be used to study how migration of cancer cells and nerves can be controlled. These interesting findings have now been published in the Journal of Biological Chemistry.03.27.08
Advanced Cancer Therapeutics Secures Exclusive License To Second Anti-Cancer Therapeutic From The University Of Louisville’s Brown Cancer Center
Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, announced that it has signed an exclusive license to develop and market 4-IPP and its related compounds, discovered by scientists at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center). Brown Cancer Center researchers Dr. Robert Mitchell and Dr.Amrubicin(R) Receives FDA Orphan Drug Designation For The Treatment Of Small Cell Lung Cancer
Celgene Corporation (NASDAQ: CELG) announced that Amrubicin has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer. FDA’s Orphan Drug Act was designed to encourage the development of products that demonstrate promise for the diagnosis, prevention and/or treatment of life-threatening or very serious conditions that are rare and affect 200,000 persons or less in the United States.
